It has been demonstrated that Myeloid Derived Suppressor Cells (MDSC) are expanded in HIV-1 chronically infected individuals. The phase of HIV infection during which MDSC expansion occurs, and the mechanisms that regulate this expansion remain to be established. In this study we evaluated the frequency of MDSC in patients during primary HIV infection, and factors involved in MDSC control.
Patients with primary (PHI, n=51) and chronic (CHI, n=26) HIV infection were enrolled before and one year after therapy initiation. At baseline, median CD4 T cell count was 588 cells/mm3 (IQR 470-830) in PHI, and 499 cells/mm3 (IQR 148-644) in CHI. Median viral load was 5.31 Log RNA copies/ml (IQR 4.33-6.16) in PHI and 4.75 Log RNA copies/ml (IQR 4.44-5.34) in CHI. MDSC frequency and function were evaluated by flow cytometry. Cytokine levels were evaluated by Luminex technology. Spearman rho was calculated to evaluate correlations. Wilcoxon/Mann-Whitney test was used to compare continuous parameters.
We found that, before therapy initiation, granulocytic MDSC (Gr-MDSC) frequency was higher in PHI compared to healthy donors (p<0.0001), but lower than CHI (p=0.02). Interestingly, Gr-MDSC expansion was already observed in the early phases of HIV infection (Fiebig II/III), but it was not associated to HIV viral load and CD4 T cell count. As previously demonstrated in CHI, Gr-MDSC from PHI inhibit HIV-specific T cell response, suggesting a detrimental role of Gr-MDSC. Interestingly, in PHI Gr-MDSC frequency was inversely correlated with plasmatic level of TRAIL (r= -0.52, p= 0.003), while a direct correlation was observed in CHI (r= 0.6, p= 0.029). Further, lower level of GM-CSF was observed in PHI compared with CHI (p= 0.04). In vitro experiments demonstrated that, differently from CHI, recombinant TRAIL induced apoptosis of Gr-MDSC from PHI, an effect that can be abrogated by GM-CSF. Antiretroviral therapy was not able to affect Gr-MDSC frequency in both PHI and CHI. However, in PHI an inverse correlation between Gr-MDSC frequency and the number of CD4 T cells was observed (r= -0.39, p= 0.029), suggesting that Gr-MDSC persistence, after treatment of acute infection, could be associated with a worst CD4 T cell recovery.
We found that suppressive Gr-MDSC are expanded very early during PHI, and correlate with CD4 T cell count after therapy. TRAIL and GM-CSF may play a role in regulating Gr-MDSC expansion, thus opening new perspectives for immune-based strategies.